Bristol Myers Pauses Zola-Cel Program to Review Clinical Data
BMY sits 58% above its 52-week low of $42.52.
Summary
Bristol Myers Squibb has voluntarily paused its Zola-Cel program to review clinical data. The company spokesperson confirmed the pause, but no details were provided on the specific safety or efficacy concerns prompting the review. This is a significant development for a clinical-stage asset, as pauses often signal potential issues that could delay or derail development. The news comes amid a strong run for BMY, with the stock trading near its 52-week high following a strong Q2 and positive pipeline updates. Investors will be watching for further clarity on the nature of the data review and any impact on the program's timeline.
Updates
· Reuters — Oxford BioMedica shares fell 14.7% in London trading following the pause.
At the time of this announcement, BMY was trading at $67.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $136.5B. The 52-week trading range was $42.52 to $68.64. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.